Skip to main content

Table 1 Haemodynamic effects of BAY 63–2521, 2.5 mg

From: BAY 63–2521, an oral soluble guanylate cyclase stimulator, has a favourable safety profile, improves cardiopulmonary haemodynamics and has therapeutic potential in pulmonary hypertension

 

SBP (mmHg)

SVR (dyn·s·cm-5)

mPAP (mmHg)

PVR (dyn·s·cm-5)

Cardiac index (L/min/m2)

vs baseline

-28.6***

-545.9***

-5.1**

-168.1*

0.95***

Vs iNO

-25.7***

-541.5***

-3.1

-132.9*

0.89***

  1. *P < 0.05; **P < 0.005; ***P < 0.0001
Back to article page

BMC Pharmacology

ISSN: 1471-2210